Brought to you by 
Parke-Davis and Ligand develop estrogen receptor modulators
14 Aug 2000
Executive Summary
Warner-Lambert's Parke-Davis division and Ligand Pharmaceuticals have entered an agreement to jointly accelerate development of selective estrogen receptor modulators (SERMs). In exchange for worldwide rights to any resulting product, Parke-Davis will pay up to $13mm in research payments over three years, in addition to a (uf)$2.5mm up-front equity investment, payment of development and marketing costs, milestones, and royalties.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Parke-Davis and Ligand develop estrogen receptor modulators
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice